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Clinical featuresGM1 gangliosidosis is a lysosomal disorder caused by β-galactosidase deﬁciency due tomutations in the GLB1 gene.
It is a rare neurodegenerative disorder with an incidence of about 1:100,000–1:200,000 live births worldwide. Here
we review GLB1mutations and clinical features from 65 Brazilian GM1 gangliosidosis patients. Molecular analysis
showed 17 different mutations and c.1622–1627insGwas themost frequent, accounting for 50% of the alleles. Cog-
nitive impairment was the main clinical sign, observed in 82% of patients, followed by hepatosplenomegaly ob-
served in 56% of patients. It was possible to establish a signiﬁcant correlation between age at onset of symptoms
preceding the ﬁrst year of life and the presence of the mutation c.1622–1627insG (p=0.03). Overall our ﬁndings
differ from literature and represent the exclusive genotypic proﬁle found in Brazilian GM1 gangliosidosis patients.
© 2012 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
Hereditary deﬁciency of lysosomal acid β-galactosidase (EC 3.2.1.23)
is expressed clinically as two different diseases: GM1 gangliosidosis and
mucopolisaccharidosis IV B (Morquio B) (Suzuki et al., 2001). This deﬁ-
ciency occurs due to mutations in the GLB1 gene, although the differ-
ences that lead to GM1 gangliosidosis or Morquio B are not completely
understood. GLB1 is located on chromosome 3 at 3p21.33 (Takano and
Yamanouchi, 1993) and is composed of 62.5 kb divided into 16 exons
(Morreau et al., 1989). It has been shown that more than 130 different
mutations are responsible for Morquio B or GM1 gangliosidosis pheno-
types (Brunetti-Pierri and Scaglia, 2008; Callahan, 1999; Hofer et al.,
2009). However, patients with intermediate phenotype have also been
described (Giugliani et al., 1987; Mayer et al., 2009).
GM1 gangliosidosis is a neurodegenerative condition for which
three main clinical forms have been identiﬁed: type I (infantile,
OMIM# 230500), type II (late infantile/juvenile, OMIM# 23060),
and type III (adult, OMIM# 23650) (Brunetti-Pierri and Scaglia,
2008). The severe infantile phenotype (type I) is characterized by
psychomotor regression by the age of 6 months, visceromegaly, cherryetabolism; HCPA, Hospital de
CP, Single-stranded conforma-
phoresis; SIFT, Sorting Intoler-
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ital de Clínicas de Porto Alegre,
, Brazil. Tel.: 55 51 3359 8841/
vier OA license.red spot, facial and skeletal abnormalities. GM1 gangliosidosis type II
usually starts between 7 months and 3 years of age with slowly pro-
gressive neurological signs including early motor problems, strabis-
mus, muscle weakness, seizures, lethargy, and susceptibility to
infections. Dysmorphisms and skeletal changes are less severe than
seen in type I. The adult form (type III), the attenuated phenotype,
with onset between 3 and 30 years, is characterized by cerebellar
dysfunction, dystonia, slurred speech, short stature and mild verte-
bral deformities (Callahan, 1999; Suzuki et al., 2001). The incidence
of GM1 gangliosidosis is considered to be between 1:100,000 and
1:200,000 live births (Sinigerska et al., 2006), although higher frequen-
cies have been described for speciﬁc regions, such as Malta (1:3,700)
(Lenicker et al., 1997). The estimated incidence in Brazil has been calcu-
lated to be 1:13,317 live births, and the carrier frequency was found to
be 1:58 (Baiotto et al., 2011). Mutation analysis performed in Brazilian
patients detected the presence of mutations c. 1622–1627insG and/or
p. R59H in 62.5% and 57.7% of the alleles (Baiotto et al., 2011; Silva et
al., 1999). Here, we report the results of GLB1 gene mutation screening
in 65 patients with GM1 gangliosidosis and clinical data in 32 of them.
2. Materials and methods
2.1. Patients and ethics
The present work has been approved by the Ethics Research Com-
mittee of Hospital de Clinicas de Porto Alegre, followed the Declaration
of Helsinki, and the standards established by the author's Institutional
Review Board and granting agency.
Table 1
Allele frequencies in 65 Brazilian GM1 gangliosidosis patients (n=130 chromosomes).
Alleles Frequency Number of alleles Reference
c.1622–1627insG 0.51 67 Silva et al., 1999
p.R59H 0.19 25 Morrone et al., 1997
c.638-641insT 0.02 3 Silva et al., 1999
p.R201H 0.01 2 Kaye et al., 1997
p.R208C 0.01 2 Boustany et al., 1993
p.Y36S 0.01 2 Vieira, 2006
p.V240M 0.01 2 Silva et al., 1999
p.Q580R 0.01 2 New
p.R38G 0.007 1 Vieira, 2006
p.F63Y 0.007 1 Vieira, 2006
p.Y64F 0.007 1 Vieira, 2006
p.R121S 0.007 1 Silva et al., 1999
c.895–896insC 0.007 1 Silva et al., 1999
c.2(+1)G>A 0.007 1 Georgiou et al., 2005*
p.D491N 0.007 1 Silva et al., 1999
p.R590S 0.007 1 New
p.C626R 0.007 1 New
ND 0.12 16 –
ND=not determined.
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diagnosed at the Laboratory of Inborn Errors ofMetabolism fromHospi-
tal de Clínicas de Porto Alegre (LREIM/HCPA), Brazil. Clinical suspicion
was conﬁrmed by low enzyme activity of β-galactosidase in leukocytes
or ﬁbroblasts. Residual β-galactosidase activity from patients was mea-
sured using the artiﬁcial 4-methylumbelliferyl β-galactopyranoside
substrate (Sigma).
2.2. Molecular analysis
Molecular data were obtained from patient's records and most of
the mutations have been published elsewhere (Baiotto et al., 2011;
Silva et al., 1999; Vieira, 2006). For the 27 out of 65 patients not pre-
viously analyzed, genomic DNA was extracted from peripheral blood
leukocytes using the Easy-DNA Kit (Invitrogen). Molecular analysis
was performed by PCR using primers and conditions described by
Silva et al. (1999). All exons were screened by Single Strand Confor-
mational Polymorphism (SSCP) analysis followed by automated DNA
sequencing to establish the speciﬁc mutation in each patient. The
conditions used for SSCP varied according to the exons that were
being analyzed: 8% or 12% polyacrylamide-agarose gel electrophore-
sis (PAGE) at room temperature. Amplicons with mobility shift were
puriﬁed with Exo-SAP (GE Healthcare) and submitted to automated
sequencing on ABI 3100 Genetic Analyzer using BigDye v3.0 (Life
Technologies).
Novel mutations were analyzed in silico using computer programs to
predict the effect on protein. PolyPhen2 was accessed at http://genetics.
bwh.harvard.edu/pph2/ using protein sequenceNP_000395.2 (Adzhubei
et al., 2010). SIFT (Sorting Intolerant from Tolerant) was accessed at
http://sift.jcvi.org using protein sequence ENSP00000306920 (Kumar
et al., 2009). In addition, novel mutations were searched at the 1000 ge-
nomes project (Durbin et al., 2010) (www.1000genomes.org) that con-
tains data from different population groups.
2.3. Clinical features
Clinical information was obtained from patient's records. Correla-
tion between age at onset of symptoms and the presence of mutation
was analyzed using chi-square test with Fisher's exact test.
3. Results
3.1. Molecular analysis
From 1982 to 2012, 65 patients were diagnosed with GM1
gangliosidosis at LREIM/HCPA and had their DNA analyzed. The molec-
ular and clinical characteristics of some of these patients have been pre-
viously reported (Baiotto et al., 2011; Silva et al., 1999; Vieira, 2006). For
the 27 previously unreported patients, sequencing of exonswithmobil-
ity shift detected by SSCP, revealed three novel mutations. All newmu-
tations are missense (p.Q580R, p.R590S and p.C626R), and located in
exons 15 and 16. Taken together, the 65 patients present 17 different
mutations: 13 missense mutations, 3 frameshift mutations and one
splice mutation (Table 1 and Suppl. Table 1).
The three novel mutations were analyzed in silico by SIFT and
PolyPhen. PolyPhen predicted that p.R590S and p.C626Rwould be prob-
ably damaging and p.580Rwould be possibly benign. On the other hand,
SIFT predicted that p.Q580R and p.R590S would be damaging, whereas
p.C626R would be tolerated. In addition, these changes were searched
at the 1000 genomes (www.1000genomes.org) and none of them was
found (for instance, p.S532G has a frequency of 5.8%).
The c.1622–1627insG was the most frequent mutation, found in 67
out of 130 mutated alleles, accounting for 51.5% of the alleles found. It
is followed by p.R59H mutation, which showed a frequency of 19.2%
(25/130). The other mutations were found in only one or two alleles
(Table 1). In 16 alleles the disease-causingmutationwas not determined,in part due to the lack of enough biological material. However, the possi-
bility of gross deletions may not be excluded, as these were not investi-
gated by whole gene sequencing at genomic and cDNA level.
3.2. Clinical and biochemical features
This is a retrospective study in which clinical information was
obtained from patients' records, thus, we only had access to clinical
information of 32 of these patients. For 32 of these patients, bio-
chemical reports were available to obtain the levels of enzyme activ-
ity for β-galactosidase (Table 2). Residual activity in leucocytes or
ﬁbroblasts from patients, measured using 4-methylumbelliferyl-β-
galactopyranoside artiﬁcial substrate, varied from 1.74 to 14 nmol/
h/mg protein on leukocytes and 5–33 nmol/h/mg protein on ﬁbro-
blasts. The average enzyme activity of β-galactosidase was 6.5 nmol/
h/mg protein on leukocytes (normal reference value: 78–280 nmol/
h/mg protein); and 19 nmol/h/mg protein on ﬁbroblasts (normal
reference value: 394–1440 nmol/h/mg protein). Even though neur-
aminidase assay has not been performed to exclude the diagnosis
of galactosialidosis, all patients had at least one mutated allele in
GLB1, thus conﬁrming the diagnostics of GM1 gangliosidosis.
Five patients had the infantile form of the disease, 15 patients had
the juvenile form and 9 had the adult form. Cognitive impairment was
the main disease manifestation, observed in 78% of patients; followed
by hepatosplenomegaly that was observed in 59% of the patients ana-
lyzed (Table 2). Other frequent clinical signs were multiple dysostosis
(37%), hypotonia (34%), coarse facies (31%), macular cherry-red spots
(21%), seizures (18%), ataxia (12%), and dystonia (12%).
Ophthalmologic ﬁndings observed included nystagmus, squint,
hypertelorism and amaurosis. Other involvements of the central ner-
vous system were characterized by macrocephaly, hydrocephalus,
cerebellar atrophy, dysarthria, speech delay, and leukodystrophy. Fi-
nally, clinical ﬁndings involving the bone structure were kyphosis,
espondilo-epiphyseal dysplasia, kyphoscoliosis, skull thickness, and
generalized skeletal deformities.
3.3. Genotype–phenotype correlations
No clear genotype–phenotype relationship could be established for
most patients. The most frequent mutation, c.1622–1627insG, was asso-
ciated with cognitive delay and hypertonia in homozygous patients and
ophthalmic ﬁndings in compound heterozygous patients (Table 2). En-
zyme activity was also highly variable, even for patients with the same
Table 2





CI HY Seizures Ataxia Dystonia Facial
features
HS DY CRS Other
1 c.1622–1627insG/c.1622–1627insG 13.0a 9 m + − − − − + + − −
2 c.1622–1627insG/c.1622–1627insG 9.3a 1 y + + − − − − − − + Amaurosis
3 c.1622–1627insG/c.1622–1627insG 7.8a 2 m + + + − − − + − −
4 c.1622–1627insG/c.1622–1627insG 7.1a 10 m − + − − − − + + +
5 c.1622–1627insG/c.1622–1627insG 6.3a 1 y + + − − − + + + − Hernia, SA
6 c.1622–1627insG/c.1622–1627insG 5.0b − − − − − − − + − − infant
7 c.1622–1627insG/c.1622–1627insG 1.74a - − − − − − − − − −
8 c.1622–1627insG/c.1622–1627insG n.a. 1 y + + − − − − + − −
9 c.1622–1627insG/c.1622–1627insG n.a. 11 m + − − − − + + − MS
10 c.1622–1627insG/c.1622–1627insG n.a. 7 y + − − − − − + − − Hydrocephalus
11 c.638–641insT/c.1622–1627insG 4.8a – + − − − − − + − − Macrosomia
12 c.638–641insT/c.1622–1627insG 6.0a 7 m + + − − − + + − + Leukodystrophy
13 c. 638–641insT/c.1622–1627insG n.a. 1 y − − − − − − − − −
14 p. Y36S/c.1622–1627insG 5.0a 9 m + − − − − + + + +
15 p. R38G/c.1622–1627insG 5.0a 4 m + − + − − − − − + ST , MS, hypertonia, hydrocele
16 p.R208C/c.1622–1627insG 4.0a 5 m + + + − − + + + −
17 p.R59H/c.1622–1627insG 13a 2 m + + + − − − + − − MS, hernia
18 p.R59H/c.1622–1627insG 3.0a 9 m + − − − − − + − −
19 p.R59H/c.1622–1627insG 3.0a 9 m + + + − − + − − − Nystagmus
20 2(+1)G>A/c.1622–1627insG 3,6a 1 y + − − − − − + − −
21 p. F63Y/c.1622–1627insG 4.0a 15 y − − − + − − − − − Dysarthria
22 c. 1622–1627insG/ND 4.0a 1 y + + − + + + + + − ST, MC, kyphoscoliosis,
hypertelorism
23 c. 1622–1627insG/ND 5.9a 6 m + − − − − − + − +
24 c. 1622–1627insG/ND 7.0a 3 y − + − + + − − + − Espondilo-epiphyseal dysplasia
25 c. 1622–1627insG/ND 9.0a 11 y + − − − + − − + − SA, speech delay
26 c. 1622–1627insG/ND 11.0a 8 y + − − − + − − + − SA, squint
27 p.R59H/ND 4.15a 7 m + − − − − − − − −
28 p.R59H/ND 33.0b 13 y + − − − − − − + − Morquio B phenotype
29 p.R59H/ND n.a. 4 y − − + + − + + − − MC, hypertriglyceridemia, CA
30 p.R59H/ND n.a. 15 y + − − − − − − + −
31 p. Y64F/ND n.a. 8 y + − − − − − − + −
32 p.Q580R/p.Q580R 14.0a 9 m + − − − − + + + +
Legend: β-galactosidase activity is presented in nmol/h/mg protein; m, month; y, year; CI, cognitive impairment; CRS, cherry-red spots; HS, hepatosplenomegaly; ST, skull thick-
ness; SA, skeletal abnormalities; MS, Mongolian spots; MC, macrocephaly, CA, cerebellar atrophy, DY, Dysostosis; HY, Hypotonia; + ,presence; −, absence; ND, not determined.
a On leukocytes (normal reference: 78–280).
b On ﬁbroblasts (normal reference: 394–1440).
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enzyme activity results ranging from 1.74 to 13 nmol/h/mg protein.
The age at onset of symptoms ranged from 2 months to 15 years.
According to the Fisher's exact test there is a signiﬁcant correlation be-
tween age at onset of symptoms preceding the patient's ﬁrst year of life
and the presence of mutation c.1622–1627insG (p=0.03) (Table 3).Table 3
Correlation between age at onset and the presence of c.1622–1627insG. Fischer exact
test.
Mutation Number of patients p Value
≤ 1 year >1 year
1622–1627insG 19 4 p=0.033
Other mutations 2 44. Discussion
GM1 gangliosidosis is a rare and heterogeneous disease. Here we re-
port the characteristics of a large series of Brazilian patients. Molecular
analysis of 65 patients revealed the presence of 17 different alleles in
the GLB1 gene. The most frequent mutation was c.1622–1627insG,
present in 50% of the alleles. This mutation has only been reported in
Brazilian patients so far, except for one patient from Uruguay described
by Santamaria et al. (2007). Silva et al. (1999) found a frequency of
42.8% for this mutation. The second most frequent mutation in this
work was p.R59H, present in 19% of the alleles. The p.R59H mutation
was ﬁrst described by Morrone et al. (1997) in an Italian patient.
Santamaria et al. (2006) observed this allele in 27.9% of patients.
Santamaria et al. (2006) and Sinigerska et al. (2006) suggested that
this mutation is of Gypsy origin and that its presence in South America
is a reﬂection of Gypsy diaspora. Although no information on ancestors
was obtained from the patients, one could suggest that Italian immi-
grants who came to Brazil in the 18th Century would be responsible
for the introduction of thismutation in the country. However, statements
about the ethnic origin of Brazilian patients are complex. Several studies,
particularly from Pena and co-workers have shown that no simplecorrelation can be drawn from color and genetic background in Brazil
(Pena et al., 2009; Pena et al., 2011).
Silva et al. (1999) found a combined frequency of 62.5% for these
two mutations in patients, similar to the one found by Baiotto et al.
(2011), which was 57.7%. In the present work the two mutations ac-
count for 69% of alleles. This number is quite high for a heterogeneous
genetic disorder like GM1 gangliosidosis, for which about 100 muta-
tions have been described (Brunetti-Pierri and Scaglia, 2008). These
data suggest a founder effect, despite Baiotto et al. (2011) were not
able to show it.
In GM1 gangliosidosis, a genotype–phenotype correlation is difﬁcult
to be drawn (Caciotti et al., 2011). Phenotypes vary on onset and sever-
ity, caused by GM1 ganglioside accumulation in nervous tissue and by a
highly variable storage of glycosaminoglycans and glycopeptides in vis-
ceral and skeletal tissues (Hofer et al., 2009). Asmost of the patients are
compound heterozygous, a correlation between GLB1 mutations and
the resulting phenotypes could not be easily established except in the
case of c.1622–1627insG homozygous patients. Most diagnosed pa-
tients in our series have the infantile or juvenile form of disease, as a re-
sult of c.1622–1627insG, the most frequent mutation. It is associated to
116 F. Sperb et al. / Gene 512 (2013) 113–116early onset of the disease, usually before 1 year of age and thus related
to a severe phenotype. As expected, we found that signs and symptoms
of central nervous system involvement were present in most cases.
One explanation for the 16 unidentiﬁed alleles among patients is a
limitation of the technique used, the SSCP. The reported accuracy of
the technique is 60% to 90%, varying according to the amplicon
(Weber et al., 2005). In addition,many of these patients had been inves-
tigated over 10 years ago and for many of them DNA was no longer
available for new analysis.
In the present study the classic features such as coarse facial fea-
tures (31%), cherry-red macula (21%), hepatosplenomegaly (59%),
and dysostosis (37%), were not constantly present, at least at the
time of diagnosis. Our results were different from those found in a lit-
erature review by Brunetti-Pierri and Scaglia (2008), which found the
following percentages: facial features (84%), cherry-red macula (42%),
hepatosplenomegaly (66%), skeletal abnormalities (83%), seizure (0.8%)
and hypotonia (88%). These differences may be due to the exclusive ge-
notypic proﬁle found in the Brazilian population, although the possible
undervaluation of patients in our series cannot be excluded.
In conclusion, thiswork presents further data onGM1 gangliosidosis
genotype–phenotype correlations. The most common mutation in
Brazilian patients, c.1622–1627insG, was associated with age at onset
before the ﬁrst year of life.
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